Glaxo Zofran
Executive Summary
The company has no plans for additional studies of Zofran in alcoholism. Data from an investigator-initiated NIH trial of the anti-emetic ondansetron for the treatment of early-onset alcoholism was published in the Aug. 23 Journal of the American Medical Association. Glaxo issued a three page "fact sheet" coinciding with the JAMA publication, emphasizing that Zofran is not indicated for alcoholism. The investigator is planning a five-year study of 320 patients at the University of Texas Health Science Center, San Antonio. The alcoholism trials are using a very low dose of Zofran (4 mcg/kg) compounded from Glaxo's marketed tablets
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth